Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes

ALK FISH analyses of multiple specimens occasionally yield inconsistent intersample results in lung cancer patients, posing clinical challenges requiring intensive analysis of all potential causative pre- and post- analytic factors. In this study, 19 patients (8M/11F) with inconsistent intersample A...

Full description

Bibliographic Details
Main Authors: Zhenya Tang, Hui Chen, Lingzhi Hong, Guilin Tang, Gokce A. Toruner, Wei Wang, Sinchita Roy Chowdhuri, Wei Yin, Hai Suk Jung, Jun Gu, Mark J. Routbort, Jianjun Zhang, Joseph D. Khoury, L. Jeffrey Medeiros
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
ALK
Online Access:https://www.mdpi.com/2072-6694/12/7/1903
id doaj-b8a563250ccb4bd993566d9c4b70dd68
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Zhenya Tang
Hui Chen
Lingzhi Hong
Guilin Tang
Gokce A. Toruner
Wei Wang
Sinchita Roy Chowdhuri
Wei Yin
Hai Suk Jung
Jun Gu
Mark J. Routbort
Jianjun Zhang
Joseph D. Khoury
L. Jeffrey Medeiros
spellingShingle Zhenya Tang
Hui Chen
Lingzhi Hong
Guilin Tang
Gokce A. Toruner
Wei Wang
Sinchita Roy Chowdhuri
Wei Yin
Hai Suk Jung
Jun Gu
Mark J. Routbort
Jianjun Zhang
Joseph D. Khoury
L. Jeffrey Medeiros
Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
Cancers
lung cancer
ALK
fluorescence in situ hybridization (FISH)
next-generation sequencing (NGS)
RNA sequencing (RNA-seq)
tyrosine kinase inhibitor (TKI)
author_facet Zhenya Tang
Hui Chen
Lingzhi Hong
Guilin Tang
Gokce A. Toruner
Wei Wang
Sinchita Roy Chowdhuri
Wei Yin
Hai Suk Jung
Jun Gu
Mark J. Routbort
Jianjun Zhang
Joseph D. Khoury
L. Jeffrey Medeiros
author_sort Zhenya Tang
title Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
title_short Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
title_full Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
title_fullStr Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
title_full_unstemmed Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes
title_sort inconsistent intersample alk fish results in patients with lung cancer: analysis of potential causes
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2020-07-01
description ALK FISH analyses of multiple specimens occasionally yield inconsistent intersample results in lung cancer patients, posing clinical challenges requiring intensive analysis of all potential causative pre- and post- analytic factors. In this study, 19 patients (8M/11F) with inconsistent intersample ALK FISH results were analyzed, representing 4.9% of patients assessed ≥ twice in our institution. Fifteen patients received ALK tyrosine kinase inhibitor(s) (TKIs). Nine patients died, and ten were alive for 8 to 74-month follow-ups (median, 40 months). Through strict and stringent laboratory and case-review policies, all postanalytic factors were excluded. Correlating clinical information, ALK results obtained by RNA sequencing (RNA-seq) and other concurrent tests, several pre-analytic factors were determined. A suboptimal specimen was likely the cause in three patients, supported by the failure of one or more concurrent tests or discrepant results between FISH and RNA-seq. ALK inhibition by TKIs might have been responsible for the change of <i>ALK</i> status from positive to negative in eight patients. Other potential explanations include the existence of multiple primary lung cancer lesions, tumor heterogeneity, and the clonal evolution of tumor cells, related or not to ALK TKI therapy. This study is helpful for both pathologists and clinicians encountering inconsistent and/or discrepant intersample results.
topic lung cancer
ALK
fluorescence in situ hybridization (FISH)
next-generation sequencing (NGS)
RNA sequencing (RNA-seq)
tyrosine kinase inhibitor (TKI)
url https://www.mdpi.com/2072-6694/12/7/1903
work_keys_str_mv AT zhenyatang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT huichen inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT lingzhihong inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT guilintang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT gokceatoruner inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT weiwang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT sinchitaroychowdhuri inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT weiyin inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT haisukjung inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT jungu inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT markjroutbort inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT jianjunzhang inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT josephdkhoury inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
AT ljeffreymedeiros inconsistentintersamplealkfishresultsinpatientswithlungcanceranalysisofpotentialcauses
_version_ 1724802398221762560
spelling doaj-b8a563250ccb4bd993566d9c4b70dd682020-11-25T02:35:57ZengMDPI AGCancers2072-66942020-07-01121903190310.3390/cancers12071903Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential CausesZhenya Tang0Hui Chen1Lingzhi Hong2Guilin Tang3Gokce A. Toruner4Wei Wang5Sinchita Roy Chowdhuri6Wei Yin7Hai Suk Jung8Jun Gu9Mark J. Routbort10Jianjun Zhang11Joseph D. Khoury12L. Jeffrey Medeiros13Departments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartments of Hematopathology, Pathology and Thoracic/Head and Neck Medical Oncology, School of Health Professions, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USAALK FISH analyses of multiple specimens occasionally yield inconsistent intersample results in lung cancer patients, posing clinical challenges requiring intensive analysis of all potential causative pre- and post- analytic factors. In this study, 19 patients (8M/11F) with inconsistent intersample ALK FISH results were analyzed, representing 4.9% of patients assessed ≥ twice in our institution. Fifteen patients received ALK tyrosine kinase inhibitor(s) (TKIs). Nine patients died, and ten were alive for 8 to 74-month follow-ups (median, 40 months). Through strict and stringent laboratory and case-review policies, all postanalytic factors were excluded. Correlating clinical information, ALK results obtained by RNA sequencing (RNA-seq) and other concurrent tests, several pre-analytic factors were determined. A suboptimal specimen was likely the cause in three patients, supported by the failure of one or more concurrent tests or discrepant results between FISH and RNA-seq. ALK inhibition by TKIs might have been responsible for the change of <i>ALK</i> status from positive to negative in eight patients. Other potential explanations include the existence of multiple primary lung cancer lesions, tumor heterogeneity, and the clonal evolution of tumor cells, related or not to ALK TKI therapy. This study is helpful for both pathologists and clinicians encountering inconsistent and/or discrepant intersample results.https://www.mdpi.com/2072-6694/12/7/1903lung cancerALKfluorescence in situ hybridization (FISH)next-generation sequencing (NGS)RNA sequencing (RNA-seq)tyrosine kinase inhibitor (TKI)